Description du projet
Un nouveau souffle pour le diagnostic du cancer gastrique
Le diagnostic à un stade précoce du cancer gastrique est associé à une forte probabilité de guérison. Toutefois, le manque d’outils de dépistage fiables et non invasifs entrave les avancées, en particulier en Europe de l’Est et en Amérique latine. Le projet VOGAS, financé par l’UE, développe un outil de dépistage non invasif du cancer gastrique pour détecter les caractéristiques des composés organiques volatils (COV). L’origine et la composition des COV chez les patients atteints d’un cancer gastrique seront analysées, et les COV identifiés seront comparés aux composés de l’haleine humaine, en recourant à une chromatographie en phase gazeuse couplée à une spectrométrie de masse et à un modèle de réaction de puce à ADN à nanoparticules d’or. Un nouveau type d’analyseur de l’haleine sera développé et validé dans des études cliniques dans des pays où la charge de la maladie est élevée.
Objectif
Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.
This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).
Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.
The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.
As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.
Champ scientifique
- natural scienceschemical sciencesinorganic chemistryinorganic compounds
- natural scienceschemical sciencesorganic chemistryvolatile organic compounds
- medical and health sciencesclinical medicineoncology
- engineering and technologynanotechnologynano-materials
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
32000 Haifa
Israël